Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $74.89M | $71.35M | $65.21M | $55.31M | $49.24M | $62.66M | $52.78M | $40.43M |
| Cost of Revenue | $20.73M | $19.64M | $15.48M | $11.65M | $11.55M | $15.39M | $12.45M | $9.63M |
| Gross Profit | $54.16M | $51.70M | $49.72M | $43.66M | $37.69M | $47.27M | $40.33M | $30.80M |
| Gross Margin | 72.32% | 72.47% | 76.26% | 78.93% | 76.54% | 75.44% | 76.42% | 76.18% |
| Operating Expenses | $88.72M | $82.26M | $84.83M | $71.22M | $60.00M | $74.20M | $60.16M | $44.41M |
| Operating Income | $-34.56M | $-30.55M | $-35.11M | $-27.56M | $-22.31M | $-26.93M | $-19.83M | $-13.61M |
| Operating Margin | -46.15% | -42.82% | -53.85% | -49.83% | -45.30% | -42.98% | -37.58% | -33.66% |
| Net Income | $-43.71M | $-30.19M | $-37.16M | $-31.19M | $-27.45M | $-29.04M | $-24.10M | $-16.06M |
| Net Margin | -58.36% | -42.31% | -56.99% | -56.39% | -55.75% | -46.35% | -45.66% | -39.72% |
| EPS (Basic) | $-1.38 | $-1.05 | $-1.38 | $-1.22 | $-1.46 | $-1.87 | $-2.69 | $-1431.28 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |